Company intelligence / Profile preview

H3 Biomedicine Inc.

Cambridge, Massachusetts, USAprnewswire.com ↗

Ownership: Private
Employees: ~70
Development stage: Phase 2

Overview

H3 Biomedicine was a precision oncology biotech focused on developing targeted small molecule drugs for genetically defined cancers. Its lead programs included a selective SF3B1 modulator for blood cancers, an ERα covalent antagonist for breast cancer, and an FGFR4 inhibitor for liver cancer. The company advanced multiple candidates into clinical trials but ceased operations in July 2022.

Therapeutic areas: HematologyOncology
Modalities: Small moleculesPrecision medicines/targeted therapies
Industry: Biotech

Drug pipeline

2 assets

H3B-6527

1 more asset in the full pipeline.

Request access →

Partnerships

Bristol Myers Squibb collaboration on RNA splicing to enhance immuno-oncology responsesAccess to FORMA Therapeutics’ technologies via Eisai strategic agreement

Beyond the preview

Go deeper on H3 Biomedicine Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on H3 Biomedicine Inc..

Explore the full profile